Press release
Multiple Myeloma Market is expected to reach USD 46.3 billion by 2034
Multiple Myeloma
Over the next decade, the multiple myeloma market is expected to see substantial growth driven by immunotherapies, proteasome inhibitors, monoclonal antibodies, and CAR-T cell therapy. Advances in genetic profiling and earlier diagnosis are further enhancing patient outcomes and expanding treatment possibilities.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70871
Market Overview
• Market Size (2024): USD 24.6 billion
• Forecasted Market Size (2034): USD 46.3 billion
• CAGR (2024-2034): ~6.7%
• Key Drivers: Increasing incidence in aging populations, strong drug pipeline, and expansion of advanced therapies in first-line settings.
• Challenges: Treatment resistance, high drug costs, and disease relapse.
• Leading Players: Johnson & Johnson, Bristol Myers Squibb, AbbVie Inc., Amgen Inc., Sanofi S.A., Pfizer Inc., and Takeda Pharmaceutical Company Limited.
Segmentation Analysis
By Drug Class
• Proteasome Inhibitors (Bortezomib, Carfilzomib, Ixazomib)
• Immunomodulatory Drugs (Lenalidomide, Pomalidomide, Thalidomide)
• Monoclonal Antibodies (Daratumumab, Isatuximab, Elotuzumab)
• CAR-T Cell Therapy (Idecabtagene Vicleucel, Ciltacabtagene Autoleucel)
• Alkylating Agents
• Corticosteroids
By Treatment Line
• First-Line Treatment
• Relapsed/Refractory Treatment
By End Use
• Hospitals & Cancer Centers
• Specialty Clinics
• Academic & Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary
The market is transitioning toward early-line use of monoclonal antibodies and combination regimens, while CAR-T therapy and bispecific antibodies are emerging as transformative options for heavily pretreated patients.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70871/multiple-myeloma-market
Regional Analysis
North America
• Holds ~48% of market revenue in 2024.
• High adoption of advanced therapies, strong clinical trial presence, and broad reimbursement coverage.
Europe
• EMA approvals expanding access to novel agents.
• Robust oncology infrastructure in Germany, France, and the UK.
Asia-Pacific
• Fastest-growing region (CAGR > 8%).
• Increasing access to advanced therapies in Japan, China, and South Korea.
• Rising incidence due to aging populations and improved detection.
Middle East & Africa
• GCC countries improving cancer care infrastructure.
• Limited access to advanced therapies in low-income regions.
Latin America
• Brazil and Mexico leading in therapy adoption and participation in global clinical trials.
Regional Summary
While North America and Europe dominate current revenues, Asia-Pacific will post the fastest growth due to expanding access to novel agents and a growing patient base.
Market Dynamics
Key Growth Drivers
1. Rising prevalence in aging populations.
2. Strong late-stage pipeline of innovative therapies.
3. Early-line adoption of monoclonal antibodies improving survival outcomes.
4. Increased CAR-T cell therapy approvals for relapsed/refractory cases.
Key Challenges
1. Treatment resistance leading to relapse.
2. High cost of advanced therapies.
3. Complex treatment sequencing decisions.
4. Limited access in resource-constrained regions.
Latest Trends
• Growth of bispecific T-cell engager (BiTE) therapies.
• Combination regimens incorporating monoclonal antibodies + proteasome inhibitors.
• Minimal residual disease (MRD) testing to guide treatment duration.
• Telemedicine adoption for follow-up and long-term monitoring.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70871
Competitor Analysis
Major Players
• Johnson & Johnson (Darzalex®, Carvykti®)
• Bristol Myers Squibb (Abecma®, Empliciti®)
• AbbVie Inc. (Venclexta® - investigational combinations in MM)
• Amgen Inc. (Kyprolis®, Blincyto® - investigational use)
• Sanofi S.A. (Sarclisa®)
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited (Velcade®, Ninlaro®)
• GlaxoSmithKline plc (Blenrep® - belantamab mafodotin)
• Bluebird Bio Inc.
• Genmab A/S
• Regeneron Pharmaceuticals Inc.
• Oncopeptides AB
• Iovance Biotherapeutics
• Legend Biotech Corporation
Competitive Summary
The multiple myeloma market is highly competitive and innovation-driven, with companies focusing on novel immunotherapies, CAR-T technology, and bispecific antibodies to improve patient survival and quality of life.
Conclusion
The multiple myeloma market is on a strong growth path as advanced immunotherapies and targeted agents become increasingly central to treatment. By 2034, expanded early-line access, personalized medicine approaches, and real-world evidence integration will redefine patient care.
Key opportunities include:
• Scaling CAR-T cell therapy access worldwide.
• Developing resistance-proof treatment regimens.
• Expanding MRD testing adoption to optimize therapy duration.
This report is also available in the following languages : Japanese (多発性骨髄腫市場), Korean (다발성 골수종 시장), Chinese (多发性骨髓瘤市场), French (Marché du myélome multiple), German (Markt für Multiples Myelom), and Italian (Mercato del mieloma multiplo), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70871/multiple-myeloma-market#request-a-sample
Our More Reports:
Radiation induced-Oral Mucositis (RIOM) in Head and neck Cancer Market
https://exactitudeconsultancy.com/reports/70818/radiation-induced-oral-mucositis-riom-in-head-and-neck-cancer-market
Lip and Oral Cavity Cancer Market
https://exactitudeconsultancy.com/reports/70820/lip-and-oral-cavity-cancer-market
Periodontal Disease Market
https://exactitudeconsultancy.com/reports/70822/periodontal-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Myeloma Market is expected to reach USD 46.3 billion by 2034 here
News-ID: 4144027 • Views: …
More Releases from Exactitude Consultancy
Metastatic Castration-Resistant Prostate Cancer Market is expected to reach USD …
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer where the disease progresses despite androgen deprivation therapy (ADT). It is one of the most challenging forms of prostate cancer to treat, often associated with poor survival rates and high symptom burden.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70869
Over the next decade, the mCRPC market is set to expand significantly due to the growing adoption of…
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2 …
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural lining of the lungs, most often caused by prolonged asbestos exposure. It is associated with a poor prognosis due to late-stage diagnosis and limited curative options. Traditionally treated with surgery, chemotherapy, and radiation, the MPM market is undergoing transformation as immunotherapy, targeted agents, and advanced imaging gain traction.
Download Full PDF Sample Copy of Market Report…
Low-Grade Glioma Market is expected to reach USD 2.75 billion by 2034
Low-grade gliomas (LGGs) are slow-growing primary brain tumors classified as WHO grade I or II, most commonly including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. Although generally associated with better prognosis compared to high-grade gliomas, LGGs can progress to higher grades over time, necessitating long-term management.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70865
The LGG market is set for significant growth over the next decade, driven by advances in molecular profiling,…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
